

PREVIEW - ANNUAL HEALTHCARE CONFERENCE - 13TH NOVEMBER 2018



The Consilium Strategic Communications' team is delighted to be hosting its **Annual Healthcare Conference** in association with Berenberg, Cooley and Westwicke Partners. The invitation-only, free to attend, half-day event will take place on **Tuesday 13th November 2018** at the **De Vere Grand Connaught Rooms, 61 - 65 Great Queen Street, London, WC2B 5DA** starting at 12:00 GMT with lunch, and concluding at 17:30 GMT followed by networking drinks.

We have assembled a high-profile, international group of speakers representing a range of voices from across the global healthcare industry and investment community.

Panels this year include:

Venture forth

Newer and more diverse forms of venture capital are coming into the sector, changing the rules of engagement for companies seeking funding. Beyond the traditional IPO route, VC investors are now more likely to invest in public companies and Chinese money is pouring into healthcare. How should companies take advantage of this new influx of investment into the sector? And what are the implications for the broader investment model?

Adapting for advanced therapies

With ground-breaking medicines such as gene and cell therapy coming of age, how is the infrastructure of the biopharma industry, companies, regulators and governments alike, responding to the pace of change, and how will these therapies be priced and reimbursed?

The AI revolution

Artificial Intelligence has moved from blue-sky thinking to the 'Next Big Thing' in healthcare. How will AI shape treatment and policy for healthcare? How can investors best take advantage of this growing industry?

Confirmed panel speakers include:

- **Tom Lynch**, Former Chairman of Icon plc, Founder of Warner Chilcott, Former CFO of Elan plc, Chairman of Evofem Biosciences and Non-Executive Director of GW Pharma
- **Michael Hayden**, Former President of Global R&D and Chief Scientific Officer at Teva, Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine
- **Lord (Paul) Drayson**, Chief Executive Officer, Sensyne Health
- **Ken Mulvany**, Chairman and Founder, Benevolent AI
- **Jean-Pol Detiffe**, Chief Executive Officer, OncoDNA
- **Mike Townend**, Chief Investment Officer, IP Group
- **Naveed Siddiqi**, Partner, Andera Partners
- **John Brown**, Chairman, Cell Therapy Catapult
- **Chris Hollowood**, Chief Investment Officer, Syncona Partners
- **Victor Christou**, Chief Executive Officer, Cambridge Innovation Capital
- **Mike Ward**, Chief Content Officer, Scrip Pharmaceutical News
- **Eva-Lotta Allan**, Non-Executive Director
- **Tom Burt**, Partner, Crossover fund, Sofinnova Partners

This event has grown in popularity every year and last year we had over 300 registered delegates. To request an invitation to attend please contact admindcsc@consilium-comms.com

We look forward to seeing you there on the day!



MONTHLY INTELLIGENCE

MEDIA MOVES

- **David Crow** is leaving the Pharmaceuticals beat and New York to become Banking Editor at the Financial Times in London
- **Iain Withers** will be joining Reuters from the Daily Telegraph to cover Banking
- **Rosamund Urwin** is moving from the Financial Services desk at The Sunday Times to the News Desk

- **John Hodgson** has left Informa to become a freelance writer
- **Tina Tan**, former co-Editor-In-Chief at Informa's Medtech Insight, has joined the FirstWord group to head its FirstWord Medtech news and analysis product as Executive Editor

ANALYST MOVES

- **Graig Suvannavejh** has joined Goldman Sachs as its senior European Biotechnology analyst





THIS MONTH'S MOVERS AND SHAKERS

- Inivata appointed **Clive Morris** to CEO, **Stacy Chick** as CCO and **Thomas Schlumpberger** as VP Business Development
- UTILITY therapeutics appointed **Dr Francesco Granata** as Chairman
- Oncimmune appointed **Adam Hill** as CEO, **Geoffrey Hamilton-Fairley** transitions to Vice Chairman
- Oncimmune Holdings appointed **Marco Casarin** as General Manager, Oncimmune USA LLC
- NodThera appointed **Adam Keeney** as President and CEO
- Abingworth appointed **Brian Gallagher**, as Partner
- genedrive appointed **Chris Yates** as Non-Executive Director
- Silence Therapeutics appointed **David Horn Solomon** as CEO
- Akero Therapeutics appointed **Andrew Cheng** as President and CEO
- Crescendo Biologics appointed **Pavel Pisa** as CMO
- Allurion Technologies appointed **Chris Tomosivitch** as CFO
- Aura Biosciences appointed **Julie Feder** as CFO, and **Kylie Reynolds** as VP of finance
- Agios Pharmaceuticals appointed **Jackie Fouse** as CEO
- Applied Therapeutics appointed **Riccardo Perfetti** as CEO
- Roche Diagnostics announced that **Roland Diggelmann**, CEO, plans to leave the company, effective Sept. 30
- WuXi AppTec promoted **Edward Hu** from CFO to co-CEO
- Allegro Ophthalmics promoted CEO **Hampar Karageozian** to Executive Chairman, and former President, Co-founder and CMO **Vicken Karageozian** to CEO
- Kaleido Biosciences appointed **Alison Lawton** as CEO
- GlaxoSmithKline appointed **Iain Mackay** as CFO and an Executive Director on GSK's board
- UroGen Pharma appointed **Peter Pfreundschuh** as CFO, effective Aug. 20
- Celyad appointed **Filippo Petti** as CFO, effective Sept. 3
- Cell Medica appointed **Chris Nowers** as CEO
- Oncorus appointed **Ted Ashburn** CEO and President
- Pfizer announced that **Seng Hing Cheng** was named Senior VP and CSO of its rare disease research unit
- Hologic's CFO, **Bob McMahon**, plans to leave the company to become the CFO of Agilent Technologies. Chief Accounting Officer **Karleen Oberton** will take his place
- Gilead Sciences announced that CEO **John Milligan** and Chairman **John Martin** will leave the company
- Servier appointed **David Lee** as CEO



HIGHLIGHTED FUNDRAISING ACTIVITY FROM AUGUST TO SEPTEMBER 2018

COMPANY NAME	AMOUNT RAISED	TYPE OF FUNDRAISE	COUNTRY	DATE
PUBLIC COMPANY FINANCINGS				
YiChang HEC ChangJiang	\$400 million	Convertible Bonds	China	15-Aug-18
Entasis Therapeutics Inc.	\$86.3 million	IPO	US	18-Aug-18
Principia Biopharma Inc.	\$86.3 million	IPO	US	20-Aug-18
Y-mAbs Therapeutics Inc.	\$92 million	IPO	US	24-Aug-18
Sutro Biopharma Inc.	\$75 million	IPO	US	29-Aug-18
Arvinas LLC	\$100 million	IPO	US	30-Aug-18
Zai Lab Ltd.	\$150 million	Follow-on	South Africa	4-Sep-18
Adaptimmune Therapeutics plc	\$100 million	Registered Direct	UK	5-Sep-18
Zai Lab Ltd.	\$150 million	Follow-on	South Africa	6-Sep-18
Guardant Health Inc.	\$100 million	IPO	US	6-Sep-18
ProQR Therapeutics N.V.	\$90.6 million	Upsized Offering	Netherlands	7-Sep-18
Dicerna Pharmaceuticals Inc.	\$100 million	Follow-on	US	7-Sep-18
Kodiak Sciences Inc.	\$100 million	IPO	US	10-Sep-18
Endocyte Inc.	\$175 million	Follow-on	US	12-Sep-18
Galapagos N.V.	\$300 million	Follow-on	US	13-Sep-18
Xenon Pharmaceuticals Inc.	\$63 million	Follow-on	US	13-Sep-18
Principia Biopharma Inc.	\$106.3 million	IPO	US	14-Sep-18
Hua Medicine Ltd.	\$110.5 million	IPO	Hong Kong	14-Sep-18
Foamix Pharmaceuticals Ltd.	\$70 million	Follow-on	US	14-Sep-18
Principia Biopharma Inc.	\$106.3 million	IPO	US	14-Sep-18
C4X Discovery Holdings plc	\$13.2 million	Placing	UK	18-Sep-18
Argenx	\$300.6 million	Follow-on	US	18-Sep-18
Y-mAbs Therapeutics Inc.	\$96 million	IPO	US	21-Sep-18
CRISPR Therapeutics AG	\$200 million	Follow-on	Switzerland	21-Sep-18
Viking Therapeutics Inc.	\$175.8 million	Follow-on	US	21-Sep-18
Fate Therapeutics Inc.	\$125 million	Follow-on	US	21-Sep-18
Molecular Templates Inc.	\$45.1 million	Follow-on	US	21-Sep-18
PRIVATE COMPANY FINANCINGS				
Magnolia Neurosciences Corp.	\$31 million	Series A	US	13-Aug-
RDMD	\$3 million	Seed Round	US	20-Aug-18
Rakuten Aspyrian Inc.	\$150 million	Series C	US	23-Aug-18
Harbour BioMed	\$85 million	Series B	China	27-Aug-18
KaNDy Therapeutics Ltd.	\$31.9 million	Series C	UK	29-Aug-18
Tempus Labs Inc.	\$110 million	Series E	US	29-Aug-18
RootPath Inc.	\$7 million	Seed Round	US	30-Aug-18
Beijing Jacobio Pharmaceutical Co. Ltd.	\$55 million	Series C	China	31-Aug-18
Evox Therapeutics Ltd.	\$35.5 million	Series B	UK	4-Sep-18
Fulcrum Therapeutics Inc.	\$80 million	Series B	US	5-Sep-18
4D Molecular Therapeutics Inc.	\$90 million	Series B	US	5-Sep-18
Allogene Therapeutics Inc.	\$120 million	Convertible notes	US	6-Sep-18
Twentyeight-Seven Therapeutics Inc.	\$65 million	Series A	US	6-Sep-18
SCM Lifescience	\$35 million	Series C	South Korea	7-Sep-18
OncoResponse Inc.	\$40 million	Series B	US	11-Sep-18
Coda Biotherapeutics Inc.	\$19 million	Series A	US	12-Sep-18
Atreca Inc.	\$125 million	Series C	US	12-Sep-18
Galera Therapeutics Inc.	\$150 million	Series C	US	19-Sep-18
Tvardi Therapeutics Inc.	\$9 million	Series A	US	20-Sep-18
uBiome Inc.	\$83 million	Series C	US	21-Sep-18



2018

OCTOBER

- Cantor Fitzgerald Healthcare Conference**, New York (1-3 October)
- Ladenburgh Thalman Healthcare Conference**, New York (2 October)
- ARM Cell & Gene meeting on the Mesa**, La Jolla (3-5 October)
- Sachs Annual Biotech in Europe Forum**, Basel (4-5 October)
- Biotech in Europe Forum**, Basel (4-5 October)
- Sachs Annual Medtech & Digital Health Forum**, Basel (5 October)
- Cowen & Co. Annual Therapeutics Conference**, New York (9-10 October)
- BIO Investor Forum 2018**, San Francisco (17-18 October)
- BIA UK Bioscience Forum**, London (18 October)

NOVEMBER

- FT Global Pharmaceutical and Biotechnology Conference 2018**, London (5-6 November)
- BIO-Europe 2018**, Copenhagen (5-7 November)
- Credit Suisse Annual Healthcare Conference**, Scottsdale (5-7 November)
- Biotech and Money Inv€stival Showcase**, London (13 November)
- Consilium Strategic Communications Annual Healthcare Conference**, London (13 November)
- Boston Biotech Europe CEO**, London (13-14 November)
- Stifel Nicolaus Weisel Healthcare Conference 2018**, New York (13-14 November)
- Jefferies Healthcare Conference**, London (14-15 November)
- Canaccord Genuity Medical Technology and Diagnostics Forum**, New York (15 November)
- Evercore ISI Healthcare Conference**, Boston (27-29 November)
- Piper Jaffray Annual Healthcare Conference**, New York (27-29 November)
- Forbes Healthcare Summit**, New York (28-29 November)

DECEMBER

- Berenberg Bank Annual European Conference**, Surrey (3-6 December)
- Citibank Global Healthcare Conference**, New York (5-6 December)

2019

JANUARY

- BioTech Showcase 2019**, San Francisco (7-9 January)
- JP Morgan Annual Healthcare Conference**, San Francisco (7-10 January)
- Future of Healthcare Investor Forum**, London (TBD)
- Annual Needham Growth Conference**, New York (TBD)

FEBRUARY

- Annual BIO CEO & Investor Conference**, New York (11-12 February)
- RBC Capital Markets 2019 Healthcare Conference**, New York (20-21 February)
- Annual JMP Securities Technology Research Conference**, San Francisco (25-26 February)
- Annual European Life Science CEO Forum & Exhibition**, Zurich (TBD)
- Leerink Partners Global Healthcare Conference 2019**, New York (27 February-1 March)
- ASCO-SITC Clinical Immuno-Oncology Symposium**, San Francisco (28 February-2 March)
- Morgan Stanley European MedTech & Services Conference**, London (TBD)

MARCH

- Credit Suisse Healthcare One-on-One Conference**, London (5-6 March)
- Roth Capital Partners Annual Conference**, Orange County (10-12 March)
- Cowen & Co. Annual Health Care Conference**, Boston (11-13 March)
- Barclays Capital Healthcare Conference**, Miami (12-14 March)
- BIO-Europe Spring, Amsterdam**, Vienna (25-27 March)
- Raymond James Annual Institutional Investors Conference**, Orlando (TBD)
- Boston BioTech BD Conference**, Boston (TBD)
- Oppenheimer & Co. Annual Healthcare Conference**, New York (TBD)
- BioCentury Future Leaders in the Biotech Industry**, New York (TBD)
- KBC Securities Healthcare Conference**, Brussels (TBD)
- Needham & Co. Annual Healthcare Conference**, New York (TBD)

CONSILIUM IS THE OFFICIAL PR AGENCY FOR

THE ECONOMIST EVENTS WAR ON CANCER 2018

The Economist EVENTS

WAR ON CANCER EUROPE

The technological
revolution and the
future of patient
engagement

November 20th
2018

London

25% off with code CONSILIUM/DC

Register today

To book a place with an exclusive Consilium 25% discount rate, please use the code above or contact a member of Consilium's healthcare team: WarOnCancer2018@consilium-comms.com

CONSILIUM STRATEGIC COMMUNICATIONS

INTERNATIONAL HEALTHCARE COMMUNICATIONS



Leading specialist advisor
in Europe – deep sector
knowledge



Experts across
all sub-sectors of
healthcare



Unparalleled
global network



Trusted advisor to
the highest quality
international companies



Long-term
relationships

